Changeflow GovPing Pharma & Drug Safety Viral Protein Expression Patent Application
Routine Notice Added Draft

Viral Protein Expression Patent Application

Favicon for changeflow.com USPTO Patent Applications - Biotech (C12N)
Published
Detected
Email

Summary

The USPTO has published a new patent application, US20260085328A1, filed on September 8, 2023. The application describes methods and systems for producing adeno-associated virus (AAV) particles using insect cells.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

This document is a publication of a patent application filed with the USPTO, specifically application US20260085328A1, titled 'CONTROLLED EXPRESSION OF VIRAL PROTEINS'. The application, filed on September 8, 2023, details methods and systems for producing adeno-associated virus (AAV) particles, including recombinant AAV (rAAV) particles, utilizing Spodoptera frugiperda insect cells (Sf9 or Sf21) as viral production cells (VPCs).

As this is a patent application, it does not impose immediate regulatory obligations or deadlines on companies. However, it represents a new development in the field of viral vector production. Companies involved in biotechnology and pharmaceutical manufacturing should review this application to understand potential future intellectual property landscapes and emerging technologies in AAV production. No specific compliance actions are required at this stage.

Archived snapshot

Mar 27, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

CONTROLLED EXPRESSION OF VIRAL PROTEINS

Application US20260085328A1 Kind: A1 Mar 26, 2026

Inventors

Jeffrey Morley SLACK, Christopher Cain Lam NGUYEN, Peter SLADE, Ryan Joseph NISTLER, Amanda Udumma IBE-ENWO

Abstract

The present disclosure describes methods and systems for use in the production of adeno-associated virus (AAV) particles, including recombinant adeno-associated virus (rAAV) particles. In certain embodiments, the production process and system use Spodoptera frugiperda insect cells (such as Sf9 or Sf21) as viral production cells (VPCs).

CPC Classifications

C12N 15/86 C12N 2710/14044 C12N 2750/14143 C12N 2750/14152

Filing Date

2023-09-08

Application No.

19109936

View original document →

Named provisions

Abstract Inventors CPC Classifications

Get daily alerts for USPTO Patent Applications - Biotech (C12N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
September 8th, 2023
Instrument
Notice
Legal weight
Non-binding
Stage
Draft
Change scope
Minor
Document ID
US20260085328A1

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology
Activity scope
Drug Manufacturing Biotechnology Research
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Topics
Biotechnology Intellectual Property

Get alerts for this source

We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!